Marksans Pharma Limited
MARKSANS
Rank in Stocks
#7028
Marksans Pharma Limited, along with its subsidiaries, operates internationally,... Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
Share Price
$3.29
Last synced: 2026-11-09
Market Cap
$1.49B
Change (1 day)
2.22%
Change (1 year)
49.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Marksans Pharma Limited (MARKSANS)
Category
Healthcare
Operating Margin for Marksans Pharma Limited (MARKSANS)
Operating Margin as of November 2026 TTM: 19.34%
According to Marksans Pharma Limited's latest financial reports, its current operating margin (TTM) is 19.34%. At the end of 2025 the company had an operating margin of 43.04%.
Operating Margin history for Marksans Pharma Limited from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 19.34% | -55.07% |
| 2025 | 43.04% | 141.80% |
| 2024 | 17.80% | 9.94% |
| 2023 | 16.19% | -53.65% |
| 2022 | 34.93% | -12.81% |
| 2021 | 40.06% | 165.83% |
| 2020 | 15.07% | 36.13% |
| 2019 | 11.07% | 95.93% |
| 2018 | 5.65% | 179.70% |
| 2017 | 2.02% | -83.11% |
| 2016 | 11.96% | -38.89% |
| 2015 | 19.57% | 42.64% |
| 2014 | 13.72% | 38.17% |
| 2013 | 9.93% | -129.08% |
| 2012 | -34.15% | 3,091.59% |
| 2011 | -1.07% | -136.52% |
| 2010 | 2.93% | -50.59% |
| 2009 | 5.93% | -45.30% |
| 2008 | 10.84% | 45.31% |
| 2007 | 7.46% | -29.36% |
| 2006 | 10.56% | 6.56% |
| 2005 | 9.91% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 46.07% | -97.62% |
US
|
|
| 25.70% | -98.67% |
US
|
|
| 35.53% | -98.16% |
US
|
|
| 16.24% | -99.16% |
US
|
|
| 31.92% | -98.35% |
CH
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Marksans Pharma Limited's operating margin
What is Marksans Pharma Limited's operating margin?
Marksans Pharma Limited's operating margin is 19.34%, as of Nov 2026.
What was Marksans Pharma Limited's operating margin in 2025?
In 2025, Marksans Pharma Limited's operating margin was 43.04%, compared with 17.80% in 2024.
How has Marksans Pharma Limited's operating margin changed since 2020?
From 2020 to 2025, Marksans Pharma Limited's operating margin was highest in 2025 (43.04%) and lowest in 2020 (15.07%).
How does Marksans Pharma Limited's operating margin compare with similar companies?
Marksans Pharma Limited's operating margin (19.34%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Eli Lilly and Company, with 46.07%.